| Drug Type Small molecule drug | 
| Synonyms KC 1086, KC1086 | 
| Target | 
| Action inhibitors | 
| Mechanism KAT6A inhibitors(lysine acetyltransferase 6A inhibitors), KAT6B inhibitors(lysine acetyltransferase 6B inhibitors), Epigenetic drug | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Aug 2025 | |
| Metastatic Solid Tumor | Phase 1 | - | 01 Aug 2025 | |
| Relapsed Solid Neoplasm | IND Approval | China  | 01 Jul 2025 | |
| Female Genital Neoplasms | Preclinical | China  | 29 May 2024 | 





